TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04553848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented Reality
Description: Augmented Reality (AR) systems are computer-based applications that allow an individual to view a simulated environment and dynamically interact within this environment in real-time. Augmented reality activities will be chosen by the therapist based on the primary deficits assessed during baseline testing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill training
Description: The goal of each session will be to increase balance and mobility challenge by increasing speed and minimizing BWS. Appropriate BWS will be chosen at the beginning of each training session. Participants will walk for 1 minute on the treadmill at 30%, 20% and 10% BWS. Maximum walking speed will be determined at each level of BWS and the participant will spend the remainder of the session ambulating with BWS at which they were able to achieve maximum walking speed. Additional BWS will be provided up to 30% of the participant's total body weight if the treating therapist identifies safety concerns or unfavorable gait kinematics. If a safe and kinematically appropriate gait pattern is unable to be achieved at up to 30% BWS, the previously determined walking speed will be reduced to achieve a safe and appropriate walking pattern. Participants will be encouraged not to use upper extremity support while ambulating with BWS.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training
Description: The goal of each session will be to increase balance and mobility challenge by increasing speed and minimizing BWS. Appropriate BWS will be chosen at the beginning of each training session. Participants will walk for 1 minute on the treadmill at 30%, 20% and 10% BWS. Maximum walking speed will be determined at each level of BWS and the participant will spend the remainder of the session ambulating with BWS at which they were able to achieve maximum walking speed. Additional BWS will be provided up to 30% of the participant's total body weight if the treating therapist identifies safety concerns or unfavorable gait kinematics. If a safe and kinematically appropriate gait pattern is unable to be achieved at up to 30% BWS, the previously determined walking speed will be reduced to achieve a safe and appropriate walking pattern. Participants will be encouraged not to use upper extremity support while ambulating with BWS.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Over ground training/standard of care
Description: Standard of care interventions to address balance and mobility deficits will be chosen from a list of commonly used interventions in outpatient therapy. The goal of each session will be to increase balance and mobility challenge in an over ground condition focusing treatment in the following areas:~* Biomechanical Constraints~* Stability Limits~* Anticipatory Postural Adjustments~* Reactive Postural Response~* Sensory Orientation~* Stability in Gait
Study: NCT01831921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Weight Loss
Description: Changing diet, physical activity, and self-regulatory behaviors to promote weight loss.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Individual nutrition counseling will be delivered by a registered dietitian.
Study: NCT02194062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone nasal spray
Description: use 2-50 mcg sprays to each nostril two times per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide head upright
Description: (0.5 mg/2mL) to instill into each nostril in the upright position two times per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide head forward
Description: (0.5 mg/2mL) to instill into each nostril in the head forward position two times per day
Study: NCT01903070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Study: NCT00763971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine Dimesylate (LDX)
Description: 30, 50 or 70mg capsule once per day (Overencapsulated)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Hydrochloride
Description: 18, 36, or 54mg tablet one per day (Overencapsulated)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule once per day (Overencapsulated)
Study: NCT03195751

Intervention type: DEVICE
Intervention: Software development kit measurements
Description: This proprietary SDK (FocusMotion) processes user motions recorded by the hardware (accelerometer, gyroscope, magnometer). As data is collected, the software development kit (SDK) classifies the motion as repetitive or non-repetitive, and repetitive motions are further analyzed. As the user completes a movement, the SDK tracks the number of repetitions performed, technique, and rest time. The SDK can provide real-time feedback to the user regarding their form by comparing the movement to a template of an ideal motion for that particular action. The SDK is compatible with any operating system, phone, or wearable device, providing seamless integration with pre-existing technologies.

Intervention type: DEVICE
Intervention: Manual Goniometer Measurements
Description: A manual goniometer was used to measure the range of motion of the shoulder.
Study: NCT03226314

Intervention type: PROCEDURE
Intervention: stool sample
Description: study will be proposed to all patients entering emergency ward or intensive care unit in Reunion Island university hospital. Upon consent, a stool sample will be taken (either directly on emitted stools or by rectal sampling) and analysed for enterobacteriaceae.
Study: NCT03763240

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BSE
Description: BSE powder will be provided as dry mixtures in sealed, non-transparent portion size bags. Each BSE bag contains 150 μmole, equal to 0.26 g, sulforaphane at a minimum. The mixtures are suspended with appr. 1 dl water and are ingested once daily in the morning. BSE should be stored at room temperature in dry conditions.~The doses of sulforaphane contained in the BSE is not possible to get by eating fresh broccoli, thus it has to be given as an extract.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder will be provided as dry mixtures in sealed, non-transparent portion size bags. The mixtures are suspended with appr. 1 dl water and are ingested once daily in the morning.
Study: NCT00719550

Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Administered at 625mg/m2 BID orally every day while on study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Administered at 625mg/m2 BID orally every day while on study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Administered at 625mg/m2 BID orally every day while on study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Administered at 625mg/m2 BID orally every day while on study.

Intervention type: DRUG
Group type: OTHER
Intervention: Epirubicin
Description: Administered day 1 of each cycle at 50mg/m2 IV.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Administered day 1 of each cycle at 50mg/m2 IV.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Administered day 1 of each cycle at 50mg/m2 IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epirubicin
Description: Administered day 1 of each cycle at 50mg/m2 IV.

Intervention type: DRUG
Group type: OTHER
Intervention: AMG 102
Description: Investigation product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 102
Description: Investigation product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 102
Description: Investigation product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment.

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Administered day 1 of each cycle at 60mg/m2 IV.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered day 1 of each cycle at 60mg/m2 IV.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered day 1 of each cycle at 60mg/m2 IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Administered day 1 of each cycle at 60mg/m2 IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: AMG 102 placebo will be provided in similar vials as clear, colorless, sterile protein-free solution
Study: NCT04162496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Refyne
Description: Injection of Restylane Refyne with a cannula on one side of the neck and a 30 guage needle on the other side.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Refyne
Description: Injection of Restylane Refyne with a cannula on one side of the neck and a 30 guage needle on the other side.
Study: NCT04062773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRF
Description: time restricted feeding group

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal timing of food intake
Description: no time restricted feeding
Study: NCT01205438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo every 2 weeks
Description: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo every 4 weeks
Description: Administered via subcutaneous injection for 52 weeks.
Study: NCT01017068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OME
Description: 4g/100ml) dose: п gutt tid x 1/52

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OME
Description: (2g/100ml) dose: п gutt tid x 1/52

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OME
Description: (1g/100ml) dose: п gutt tid x 1/52

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OME
Description: (4g/100ml) dose: п gutt tid x 1/52

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OME
Description: (2g/100ml) dose: п gutt tid x 1/52

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OME
Description: (1g/100ml) dose: п gutt tid x 1/52
Study: NCT00108186

Intervention type: DRUG
Group type: OTHER
Intervention: Celecoxib
Description: Eight subjects will be assigned to one of three cohorts. Subjects will receive Celecoxib in escalating doses per cohort, starting with 200mg twice a day by mouth; 400mg twice a day by mouth; and increasing to 600mg twice a day by mouth, for a total of 7 days. Subjects will have blood taken before the start of Celecoxib, and after completion of 7-days of Celecoxib.
Study: NCT03891342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid bolus administration
Description: Fluid bolus administration either fast in 5 minutes or slow in 30minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid bolus administration
Description: Fluid bolus administration either fast in 5 minutes or slow in 30minutes.
Study: NCT02537548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retroperitoneal Lymph Node Dissection
Description: Undergo RPLND
Study: NCT02022085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baha Attract System
Description: The Cochlear Baha Attract System incorporates both implantable and external parts. The implantable parts include the BI300 Implant and the BIM400 Implant Magnet, which is intended to be fixated to the BI300 Implant. The external parts include the Sound Processor Magnet (SP Magnet), which, together with the Implant Magnet, constitute the transcutaneous coupling. The SP Magnet incorporates a soft material (Soft pad) at the tissue facing surface that is designed to distribute the pressure over the skin. The Baha Sound Processor attaches to the SP Magnet via a snap coupling.
Study: NCT04475666

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Replenish protein group
Description: For patients with Body mass index(BMI) \<30, use pre-ICU actual body weight(BW) for the calculation; if unavailable, use weight on ICU admission. For patients with BMI \>=30, use adjusted body weight

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard protein group
Description: For patients with BMI \<30, use pre-ICU actual BW for the calculation; if unavailable, use weight on ICU admission. For patients with BMI \>=30, use adjusted body weight
Study: NCT03890991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCOPE-DM
Description: The 12-week programme aims to support motivation and enable capability for managing diabetes. To this end, the sessions will integrate the knowledge and practical skills components offered in traditional diabetes education with psychological techniques and principles for behavioural change: problem solving, goal-setting and monitoring. The programme offers the potential for older people to learn about their condition and treatment in a psychologically-motivating and confidence-enhancing structure - as such the emphasis is on empowering individuals to make choices and lifestyle changes in line with treatment recommendations through the use of problem solving, goal setting and feedback, and not just on knowledge transfer which has not been shown to be successful in behavioural change. The content and delivery format will largely be informed by motivational interviewing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SCOPE-DM with 3 months' supply of glucometer
Description: Participants in this arm will participate in the SCOPE-DM programme and use the glucometer for 3 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SCOPE-DM with 6 months' supply of glucometer
Description: Participants in this arm will participate the in SCOPE-DM programme and use the glucometer for 6 months.
Study: NCT02029820

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RenalGuard
Description: Intravenous saline hydration matched with urine output, using the device Renalguard
Study: NCT04442191

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: This study will use convalescent plasma collected from those who have previously had COVID-19 and have been shown to have cleared the infection and made antibodies against the virus.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo arm of this study will use fresh frozen plasma that presumably does not contain antibodies against COVID-19.
Study: NCT04114188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte Immunoglobulin (Rabbit)
Description: 1st kidney transplant recipients (low risk: PRA/cPRA \< 20%, no DSA) will receive short rATG induction (2x1.5 mg/kg) given perioperatively and on first postoperative day. All patients will receive one shot Infliximab mAb at day 2. Since POD1, maintenance IS consists of Tac and tapered steroids therapy.
Study: NCT00915772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin + metformin
Description: Linagliptin tablet low dose + metformin tablet 500 mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin+metformin
Description: Linagliptin low dose tablet + metformin 1000 mg tablet bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1000 mg tablet bid
Study: NCT00918853

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: resection of adenocarcinoma of the head of the pancreas
Description: quality standard for the resection of adenocarcinoma of the head of the pancreas
Study: NCT03494751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart monitor
Description: Use of heart monitor device in the patients after acute myocardium infarct.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No heart monitor
Description: Standard monitoring by nurses.
Study: NCT02432313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Release Formulation x (MRx)
Description: Subject receives 1 dose of a MRx and is followed. 7-day washout before dosing with another formulation
Study: NCT01668407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Gait Training (RAGT)
Description: Subjects (at least 40 subjects) will undergo inpatient rehabilitation consisting of a treatment cycle using the GE-O system device, according to individually tailored exercise scheduling. The practice will include robot-assisted walking at variable speeds for 45 min with a partial body weight support (BWS). All participants started with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h before BWS will be decreased.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Gait Training (TT)
Description: Subjects (at least 40 subjects) will undergo inpatient rehabilitation consisting of a treatment cycle using the treadmill device, according to individually tailored exercise scheduling. The practice included treadmill walking at variable speed for 45 minutes. All participants will start at an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h.~All the treatment consists of 20 sessions for the lower limbs, each lasting 45 minutes, 5 days a week for 4 weeks.
Study: NCT01062139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarlin (Levocetirizine)
Description: Combination therapy compared to mono therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cosalin (Petasites hybridus CO2 extract)
Description: Combination therapy compared to mono therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosalin (Petasites hybridus CO2 extract)
Description: Combination therapy compared to mono therapy
Study: NCT00380770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic HAART Triomune : d4T, 3TC, NVP
Description: Triomune® (Cipla, Mumbai) Stavudine 40mg b.d \> 60 kg , 30mg bd \<60kg Lamivudine 150mg b.d \> 50 kg 2mg/kg \< 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
Description: Triomune® (Cipla, Mumbai) Stavudine 40mg b.d \> 60 kg , 30mg bd \<60kg Lamivudine 150mg b.d \> 50 kg 2mg/kg \< 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks) Intramuscular Bleomycin 10 U/m2 ; Intravenous Vincristine 1.4mg/m2 maximum 2mg and Intravenous Doxorubicin 20mg/m2.
Study: NCT00393796

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SUTENT
Description: 50 mg/PO once daily for four consecutive weeks with a two week rest period. Study participants who show evidence of disease progression (or are considered for removal from study for any other reason) will be unblinded. Participants receiving SU011248 will be removed from the study. Participants receiving placebo will be given the opportunity to crossover and receive SU011248.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUTENT
Description: 50 mg/PO once daily for four consecutive weeks with a two week rest period. Study participants who show evidence of disease progression (or are considered for removal from study for any other reason) will be unblinded. Participants receiving SU011248 will be removed from the study. Participants receiving placebo will be given the opportunity to crossover and receive SU011248.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00955851

Intervention type: OTHER
Intervention: Pre and post vaccination titers
Description: Titers will be obtained pre vaccination and 4 weeks post vaccination
Study: NCT03932734

Intervention type: OTHER
Intervention: survey
Description: Face-Q conversion table
Study: NCT04344691

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectus femoris stretching
Description: Patient lying prone with the non-implicated leg outside the treatment table resting on the floor. Physical therapist flexes patients knee until tension is felt. In that position 5 seconds' isometric contraction is asked and physical therapist progresses in knee flexion range of motion until new tension is felt. After three contract-relax procedures physical therapist holds the range of motion for 30 seconds.
Study: NCT05436769

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klaribact 500 mg Clarithromycin Tablet
Description: A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Klaribact 500 mg Clarithromycin Tablet
Description: A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klaricid 500 mg Clarithromycin Tablet
Description: A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Klaricid 500 mg Clarithromycin Tablet
Description: A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.
Study: NCT02626481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: patients treated with Daratumumab (16 mg/kg) and Dexamethasone (40 or 20 mg regarding age of patient)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: patients treated with Dexamethasone (40 or 20 mg regarding age of patient)
Study: NCT02342366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GHB 35 mg/kg p.o.
Description: GHB 35 mg/kg p.o.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GHB 35 mg/kg p.o.
Description: GHB 35 mg/kg p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GHB 20 mg/kg p.o.
Description: GHB 20 mg/kg p.o.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GHB 20 mg/kg p.o.
Description: GHB 20 mg/kg p.o.